PRDM9 and lung carcinoma: More importantly, combinative treatment significantly inhibited the EMT and hence impeded the in vivo tumour development via down‐regulation of an oncogenic histone methyltransferase and gene transcriptional regulator EZH2 in lung cancer cells.50